Overcoming Immunotherapy Resistance Mechanisms in Kidney Cancer
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
Initiating Conversations on Mental Health in Oncology
Boris M. Kiselev, MD, provides practical advice for oncology clinicians on how to approach and initiate conversations about a patient’s mental and emotional well-being.
Though TAS-102 Achieved ctDNA Clearance, More Work is Needed
TAS-102 had a significant impact, achieving ctDNA clearance, in patients with colorectal cancer with ctDNA-defined MRD.
A Multifaceted Approach to Managing Cancer-Related Anxiety and Depression
Boris M. Kiselev, MD, explores evidence-based interventions for managing cancer-related anxiety and depression.
Pembrolizumab Combo Improves pCR Rate in Advanced Gastric/GEJ Cancer
Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherapy.
Nogapendekin Alfa Inbakicept Combo Yields Disease Control in Glioblastoma
Results from a pilot phase 2 trial showed that all 5 patients who received treatment achieved a response or had stable disease.
Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer
The novel treatment was evaluated in a phase 2 trial and saw a clinical benefit in patients with advanced ovarian cancer.
Pioneer of Supportive Care Highlights Additional Needs in The Space
Declan Walsh, MD, highlighted how the supportive and palliative care space has evolved since he first began working in the field.
Rina-S Earns FDA Breakthrough Therapy Designation in Endometrial Cancer
Data from the phase 1/2 RAINFOL-01 trial support the agency’s regulatory decision on rinatabart sesutecan in advanced endometrial cancer.
Psycho-Oncology is a Core Component of Comprehensive Cancer Care
Boris M. Kiselev, MD, discusses the essential role of psycho-oncology in addressing patient distress, improving treatment adherence, and supporting long-term survivorship.
DecisionDx-SCC Predicts Recurrence, Guides Imaging in Squamous Cell Carcinoma
Two studies were recently published that validated the use of the DecisionDx-SCC test as a tool for the treatment of cutaneous squamous cell carcinoma.
Haystack MRD Test Earns FDA Breakthrough Device Designation in Stage II CRC
Developers launched a clinical laboratory-developed test version of Haystack MRD in late 2024 and are further expanding access for oncologists.
AI Prognostic Tool Confirms Concordance Through Epigenomic Signatures in AML
Both experimental models significantly improved upon historical clinical risk trial groups for patients with acute myeloid leukemia.
Nutrition Research Is Needed to Enhance Outcomes in Oncology
Declan Walsh, MD, highlighted the need for nutrition research to enhance oncology care.
Rusfertide Earns FDA BTD for Erythrocytosis in Polycythemia Vera
Results from the phase 3 VERIFY trial of rusfertide for erythrocytosis in patients with polycythemia vera led to the FDA decision.
FDA Clears IND for IBI363 in Squamous Non–Small Cell Lung Cancer
Developers will now initiate the phase 3 MarsLight-11 trial of IBI363 among patients with immunotherapy-resistant squamous non–small cell lung cancer.
Integrating Supportive Care Into Everyday Practice
Being proactive and quickly identifying when a patient may need the supportive care team is the best way to integrate this field into whole-person care.
PDS0101 Plus Pembrolizumab Yields Positive Survival Results in HNSCC
The median overall survival was 39.3 months with PDS0101 plus pembrolizumab in those with front-line recurrent or metastatic head and neck squamous cell carcinoma.
Cryotherapy Device Improves Oral Mucositis Outcomes After Chemotherapy Treatment
The Chemo Mouthpiece had favorable outcomes when used during and after treatment with chemotherapy among a range of patients with various types of cancer.
START Center Aims to Bring New Cancer Treatments, Trials to The Community
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.
Atezolizumab Plus Chemo Safe, Efficacious in Broader ES-SCLC Population
The median overall survival with atezolizumab plus carboplatin and etoposide was 10.6 months in patients with extensive-stage small cell lung cancer.
Elranatamab and MagnetisMM-3 Results are Superior to Real-World Multiple Myeloma Outcomes
An observational study reported that results with elranatamab for patients with RRMM from the MagnetisMM-3 trial were superior to what was observed across 5 centers in the UK.
Tackling Unmet Needs in Mantle Cell Lymphoma
Tycel Phillips, MD, highlighted the need for new therapies for patients with MCL who have relapsed on previous lines of treatment.
Addition of Radiotherapy to Systemic Chemotherapy Improves Survival in ESCC
Although radiotherapy was safe and well tolerated in patients with esophageal squamous cell carcinoma, more research is needed to confirm these results.
Navigating the Glofitamab CRL and Bispecifics’ Place in Lymphoma
Tycel Phillips, MD, spoke about the impact the glofitamab CRL had on the landscape of bispecifics in lymphoma.
pCR Does Not Correlate With Survival in Rectal Cancer
A meta-analysis did not find any correlation between pathologic complete response and overall survival or disease-free survival in patients with rectal cancer.
mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer
After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.
Pembrolizumab Combo Exhibits Sustained Clinical Benefit in Advanced RCC
Additional correlative data and further prospective clinical investigations are needed to inform biomarker-directed advanced RCC treatment.
Oxaliplatin Elicits Improved Survival in Select Patients With Stage III CRC
Significantly improved survival was observed with oxaliplatin among patients aged 60 to 70 years with stage III CRC but not among those older than 70 years.
FDA Accepts Type C Meeting for Doxorubicin-MNA in Basal Cell Carcinoma of the Skin
D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.
